Idioma:

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

Rougier, Philippe ; Sahmoud, Tarek ; Nitti, Donato ; Curran, Desmond ; Doci, Roberto ; De Waele, B ; Nakajima, Toshifusa ; Rauschecker, Helmut ; Labianca, Roberto ; Pector, Jean-Claude ; Apolone, Giovanni ; Lasser, Philippe ; Couvreur, Marie Laure ; Wils, Jacques ; Marsoni, Silvia

The Lancet (British edition), 1998-06, Vol.351 (9117), p.1677-1681 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial
Autor: Rougier, Philippe ; Sahmoud, Tarek ; Nitti, Donato ; Curran, Desmond ; Doci, Roberto ; De Waele, B ; Nakajima, Toshifusa ; Rauschecker, Helmut ; Labianca, Roberto ; Pector, Jean-Claude ; Apolone, Giovanni ; Lasser, Philippe ; Couvreur, Marie Laure ; Wils, Jacques ; Marsoni, Silvia
Assuntos: Antineoplastic agents ; Biological and medical sciences ; Cancer ; Chemotherapy ; Colorectal cancer ; Medical sciences ; Pharmacology. Drug treatments ; Surgery
É parte de: The Lancet (British edition), 1998-06, Vol.351 (9117), p.1677-1681
Descrição: There is conflicting evidence on the efficacy of regional adjuvant chemotherapy, via portal-vein infusion (PVI), after resection of colorectal cancer. We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (500 mg/m 2 fluorouracil plus 5000 IU heparin daily for 7 days). 1235 of about 1500 potentially eligible patients were randomly assigned surgery plus PVI or surgery alone (control). The patients were followed up for a median of 63 months, with yearly screening for recurrent disease. The primary endpoint was survival; analyses were by intention to treat. 619 patients in the control group and 616 in the PVI group met eligibility criteria. 164 (26%) control-group patients and 173 (28%) PVI-group patients died. 5-year survival did not differ significantly between the groups (73 vs 72%; 95% CI for difference -6 to 4). The control and PVI groups were also similar in terms of disease-free survival at 5 years (67 vs 65%) and the number of patients with liver metastases (79 vs 77%). PVI of fluorouracil, at a dose of 500 mg/m 2 for 7 days, cannot be recommended as the sole adjuvant treatment for high-risk colorectal cancer after complete surgical excision. However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin.
Editor: London: Elsevier Ltd
Idioma: Inglês

Links

View record in Pascal Francis

Voltar para lista de resultados

Anterior Resultado 10 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

Rougier, Philippe ; Sahmoud, Tarek ; Nitti, Donato ; Curran, Desmond ; Doci, Roberto ; De Waele, B ; Nakajima, Toshifusa ; Rauschecker, Helmut ; Labianca, Roberto ; Pector, Jean-Claude ; Apolone, Giovanni ; Lasser, Philippe ; Couvreur, Marie Laure ; Wils, Jacques ; Marsoni, Silvia

London: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.